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A B S T R A C T
Abstract
The purpose of this work was to modernize recommendations for evaluation, staging, and response
assessment of patients with Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL). A workshop
was held at the 11th International Conference on Malignant Lymphoma in Lugano, Switzerland, in
June 2011, that included leading hematologists, oncologists, radiation oncologists, pathologists,
radiologists, and nuclear medicine physicians, representing major international lymphoma clinical trials
groups and cancer centers. Clinical and imaging subcommittees presented their conclusions at a
subsequent workshop at the 12th International Conference on Malignant Lymphoma, leading to
revised criteria for staging and of the International Working Group Guidelines of 2007 for response.
As a result, fluorodeoxyglucose (FDG) positron emission tomography (PET)–computed tomogra-
phy (CT) was formally incorporated into standard staging for FDG-avid lymphomas. A modification
of the Ann Arbor descriptive terminology will be used for anatomic distribution of disease extent,
but the suffixes A or B for symptoms will only be included for HL. A bone marrow biopsy is no
longer indicated for the routine staging of HL and most diffuse large B-cell lymphomas. However,
regardless of stage, general practice is to treat patients based on limited (stages I and II, nonbulky)
or advanced (stage III or IV) disease, with stage II bulky disease considered as limited or advanced
disease based on histology and a number of prognostic factors. PET-CT will be used to assess
response in FDG-avid histologies using the 5-point scale. The product of the perpendicular
diameters of a single node can be used to identify progressive disease. Routine surveillance scans
are discouraged. These recommendations should improve evaluation of patients with lymphoma
and enhance the ability to compare outcomes of clinical trials.
J Clin Oncol 32:3059-3067. © 2014 by American Society of Clinical Oncology
INTRODUCTION
The availability of more effective therapies for
lymphoma and the increasingly sensitive and spe-
cific technologies for disease assessment provide
rationale for updated patient evaluation, staging,
and response criteria. These should be unambig-
uous and universally applicable and facilitate the
comparison of patients and results among studies
and the evaluation of new therapies by regula-
tory agencies.
Staging defines disease location and extent,
suggests prognostic information, allows compari-
sons among studies, and provides a baseline against
which response or disease progression can be com-
pared. Initial staging criteria were designed primar-
ily for Hodgkin lymphoma (HL)1-3 and were
superseded by the Ann Arbor classification,4 which
subdividedHLpatients into four stages and subclas-
sification A and B based on the presence of fevers to
greater than 101°F (38.3°C), weight loss, and night
sweats and which has been the most widely used
classification since its introduction. The Cotswold
classification5 first formally incorporated computed
tomography (CT) scans and introduced “X” for
bulky disease and complete remission unconfirmed
(CRu) to describe patients with a residualmass after
treatment that was most likely fibrous tissue.
The first universally accepted response criteria
for non-Hodgkin lymphoma (NHL), used also for
HL, were published in 1999 by the National Cancer
InstituteWorkingGroup6andrevised in2007by the
International Working Group (IWG)7 to incorpo-
rate positron emission tomography (PET) andbone
marrow immunohistochemistry and flow cytom-
etry in response assessment, eliminating CRu.
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After extensiveexperiencewith thesecriteria, andrecognizing the
progress made after their publication, particularly in imaging tech-
niques, a workshop was held at the 11th International Conference
on Malignant Lymphoma in Lugano, Switzerland, in June 2011,
which was attended by leading hematologists, oncologists, radia-
tion oncologists, pathologists, radiologists, and nuclear medicine
physicians, representing major lymphoma clinical trials groups
and cancer centers in North America, Europe, Japan, and Austral-
asia. The aim was to develop improved staging and response
criteria for HL and NHL, relevant for community physicians,
investigator-led trials, cooperative groups, and registration trials.
Subcommittees focused on clinical and imaging issues, and a sub-
sequent workshop at the 12th International Conference on Malig-
nant Lymphoma in 2013 led to the following revisions.
INITIAL EVALUATION
Diagnosis
Lymphoma diagnosis depends on morphology, immunohisto-
chemistry, andflowcytometry reviewedbyanexperienced lymphoma
pathologist and, where appropriate, molecular studies to accurately
categorize the lymphoma.8 A fine-needle aspirate is inadequate for
initial diagnosis. An incisional or excisional biopsy is preferred to
provide adequate tissue for these examinations, but a core-needle
biopsy can be considered when excisional biopsy is not possible9,10
and to document relapse; however, a nondiagnostic sample must be
followed by an incisional or excisional biopsy. With consent, addi-
tional paraffin-embedded, fresh-frozen tissue, or cell suspensions
should be stored for future research.
Patient Evaluation
Clinical evaluation requires a comprehensive history including
age; sex; absence/presence of fevers to more than 101°F (38.3°C),
chills, drenching night sweats, or unexplained weight loss more than
10%of bodymass over 6months; and history ofmalignancy. Fatigue,
pruritus, and alcohol-induced pain in patientswithHL should also be
noted.Whereas these factors rarely direct treatment, their recurrence
may herald disease relapse.
Physical examination includes measurement of accessible nodal
groups and the size of the spleen and liver in centimeters below their
respective costal margins in themidclavicular line. However, the sen-
sitivity of physical examination is variable among observers. There-
fore, organomegaly is formally defined by CT imaging (Table 1).
Laboratory tests and other investigations necessary for the deter-
mination of the prognostic indices for the different lymphoma sub-
types and general patient management, including assessment of
comorbidities, must be recorded.
Anatomic Staging
Historical series and prospective clinical trials have used the
Ann Arbor staging system5 to select patients and report outcomes.
Now, stage is only one component of factors in prognostic indices
increasingly used for pretreatment risk stratification and selection
of therapy.11-15
PET-CT scanning has become the standard for assessment of
response in most lymphomas.7 For HL and fluorodeoxyglucose
(FDG) -avid NHL subtypes, PET and PET-CT improve the accuracy
of staging compared with CT scans for nodal and extranodal sites.16
PET-CTleads tochange in stage in10%to30%ofpatients,moreoften
upstaging, although alteration in management occurs in fewer pa-
tients, with no demonstrated impact on overall outcome. However,
improving staging accuracy ensures that fewer patients are under-
treated or overtreated.16 PET-CT is particularly important for staging
before consideration of radiation therapy.17,18 Although most lym-
phomas are FDG avid, because of greater variability in FDG uptake,
metabolic imaging is less reliable in other lymphomas.19-24 Whereas
mantle-cell lymphoma is routinelyFDGavid, limiteddata suggest that
the sensitivity and specificity of identifyingbowel involvement are low
and should not replace other investigative measures.25,26
RECOMMENDATION FOR REVISIONS TO STAGING CRITERIA
PET-CT is already widely used for pretreatment assessment, often
outside of clinical trials, to assign stage and has already been incorpo-
rated into response assessment.7 Although physical examination re-
mains important, anddespite concerns thatmore sensitive staging can
Table 1. Criteria for Involvement of Site
Tissue Site Clinical FDG Avidity Test Positive Finding
Lymph nodes Palpable FDG-avid histologies PET-CT Increased FDG uptake
Nonavid disease CT Unexplained node enlargement
Spleen Palpable FDG-avid histologies PET-CT Diffuse uptake, solitary mass, miliary lesions, nodules
Nonavid disease CT  13 cm in vertical length, mass, nodules
Liver Palpable FDG-avid histologies PET-CT Diffuse uptake, mass
Nonavid disease CT Nodules
CNS Signs, symptoms CT Mass lesion(s)
MRI Leptomeningeal infiltration, mass lesions
CSF assessment Cytology, flow cytometry
Other (eg, skin, lung, GI tract,
bone, bone marrow)
Site dependent PET-CT, biopsy Lymphoma involvement
Abbreviations: CSF, cerebrospinal fluid; CT, computed tomography; FDG, fluorodeoxyglucose; MRI, magnetic resonance imaging; PET, positron emission tomography.
PET-CT is adequate for determination of bone marrow involvement and can be considered highly suggestive for involvement of other extralymphatic sites. Biopsy
confirmation of those sites can be considered if necessary.
Cheson et al
3060 © 2014 by American Society of Clinical Oncology JOURNAL OF CLINICAL ONCOLOGY
Downloaded from jco.ascopubs.org on September 22, 2014. For personal use only. No other uses without permission.
Copyright © 2014 American Society of Clinical Oncology. All rights reserved.
result in stage migration, impairing the use of historically controlled
data, PET-CT is critical as a baseline measurement before therapy to
increase the accuracy of subsequent response assessment27,28 (Table
1). Therefore, the consensus was that PET-CT should be recom-
mended for routine staging of FDG-avid, nodal lymphomas (essen-
tially all histologies except chronic lymphocytic leukemia/small
lymphocytic lymphoma, lymphoplasmacytic lymphoma/Walden-
stro¨m’s macroglobulinemia, mycosis fungoides, and marginal zone
NHLs, unless there is a suspicion of aggressive transformation) as the
gold standard.24
The following recommendations are intended for lymphomas
withprimarilynodal involvement, although they are also applicable to
primary extranodal diffuse largeB-cell lymphoma (DLBCL). Separate
criteria have been proposed for primary extranodal29,30 and cutane-
ous lymphomas.31
Imaging
PET-CT is preferred for staging of FDG-avid lymphomas, and
CT scan is preferred in the other lymphomas. A chest x-ray is no
longer required in lymphoma staging because it less accurate than
CT.32 Moreover, CT identifies more hilar nodes and may better
discriminate between a single large nodal mass and an aggregate of
individual nodes. Bulk is a negative prognostic factor,11,13-15 but
there is little agreement on its definition, which is disease, stage,
and treatment specific.
These criteria strongly recommend PET-CT for staging of
routinely FDG-avid histologies, especially in clinical trials. A contrast-
enhanced CT scan should be included for a more accurate measure-
mentofnodal size if required for trials; if necessary, tomore accurately
distinguish bowel from lymphadenopathy; and in the setting of com-
pression/thrombosis of central/mediastinal vessels. Contrast-
enhanced CT is also preferred for radiation planning. Variably FDG-
avid histologies should be staged with a CT scan.
For patients staged with PET-CT, focal uptake in nodal and
extranodal sites that is in keeping with lymphoma, according to the
distributionand/orCTcharacteristics, is considered involvementwith
lymphoma, including spleen, liver, bone, thyroid, and so on. For
patients staged with CT, up to six of the largest target nodes, nodal
masses, or other lymphomatous lesions that are measurable in two
diameters (longest diameter [LDi] and shortest diameter) should
be identified from different body regions representative of the
patient’s overall disease burden and includemediastinal and retro-
peritoneal disease, if involved. A measurable node must have an
LDi greater than 1.5 cm. Measurable extranodal disease (eg, he-
patic nodules) may be included in the six representative, measured
lesions. Ameasurable extranodal lesion should have an LDi greater
than 1.0 cm. All other lesions (including nodal, extranodal, and
assessable disease) should be followed as nonmeasured disease (eg,
cutaneous, GI, bone, spleen, liver, kidneys, pleural or pericardial
effusions, ascites). In patients in whom a discordant histology or
malignant transformation is suspected, a PET-CTmay identify the
optimal site to biopsy for confirmation.20,21
Tumor Bulk
A single nodal mass, in contrast to multiple smaller nodes, of 10
cm or greater than a third of the transthoracic diameter at any level of
thoracic vertebrae as determined byCT is retained as the definition of
bulky disease for HL.5 A chest x-ray is not required to determine bulk
because of its high concordancewithCT.32However, a variety of sizes
have been suggested for NHL,15,33 with limited evidence suggesting 6
cm as best for follicular lymphoma15 and 6 to 10 cm in the rituximab
era for DLBCL.34 However, none of the proposed sizes have been
validated in the current therapeutic era. Therefore, the recommenda-
tion for HL and NHL is to record the longest measurement by CT
scan, with the term X no longer necessary.
Spleen Involvement
A wide range of normal spleen sizes has been reported,35-37 re-
lated to race, body size, and height.38 A spleen may be of normal size
and still contain lymphomaormaybe enlargedas a result of variations
in blood volume, use of hematopoietic growth factors, or lymphoma-
unrelated causes. Splenic involvement is best determined by PET-CT
and may be characterized by homogeneous splenomegaly, diffuse
infiltration with miliary lesions, focal nodular lesions, or a large soli-
tary mass.39 There is no agreement on whether single, multiple, or
volumetric measurements should be used tomeasure spleen size35 or
what cutoff to use for splenomegaly. For simplicity, a single measure-
ment that correlateswellwith volume40,41 is preferable to a volumetric
measurementor estimationbyequations,with special software,which
are unlikely to be used routinely.
Most studies use 10 to 12 cm for vertical length.Our recommen-
dation is to use a cutoff for splenomegaly of more than 13 cm.
Liver Involvement
Given variability in body habitus and the impact of numerous
medical conditions, liver size by physical examination or CT scan is
not a reliable measure of hepatic involvement by lymphoma. Similar
to splenic involvement, diffusely increased or focal uptake, with or
without focal or disseminated nodules, supports liver involvement.
Bone Marrow Involvement
Bone marrow biopsy (BMB) has been standard in lymphoma
staging,5 although it is often performed evenwhen the likelihoodof
involvement is low. The high sensitivity of PET-CT for bone mar-
row involvement has recently called into question the continued
use of BMB in several commonhistologies.42-46 In one study inHL,
18% of patients had focal skeletal lesions on PET-CT, but only 6%
had positive BMB,46 all with advanced disease on PET-CT.None of
the patients would have been allocated to another treatment based
on BMB results. Patients with early-stage disease rarely have in-
volvement in the absence of a suggestive PET finding, and those
with advanced-stage disease rarely have involvement in the ab-
sence of disease-related symptoms or other evidence of advanced-
stage disease. Thus, if a PET-CT is performed, a bone marrow
aspirate/biopsy is no longer required for the routine evaluation of
patients with HL.
InDLBCL,PET-CTis alsomore sensitive thanBMBbuthasbeen
reported to miss low-volume diffuse involvement of 10% to 20% of
themarrow.42,47-49 Nevertheless, patients with clinical early-stage dis-
ease rarely have involvement in the absence of a suggestive PET find-
ing. In one study in DLBCL, 27% of patients were found to have
marrow involvement (94%byPET-CTandonly 40%byBMB). BMB
wasnegative in 21of 28patientswith focal disease onPET-CTanddid
not upstage any patients. Two cases (1.5%) of bone marrow involve-
ment went undetected by PET-CT, with a 10% infiltrate of large cells.
Thus, a PET-CT scan indicating bone or marrow involvement is
Staging and Response Assessment in Lymphoma
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usually sufficient to designate advanced-stage disease, and a BMB is
not required. Patients with a positive BMB generally have other fac-
tors consistent with advanced stage or poor prognosis.49,50 If the scan
is negative, a BMB is indicated to identify involvement by discordant
histology if relevant for a clinical trial or patient management.51
The data in all other lymphoma histologies are insufficient to
change the standard practice, and a 2.5-cm unilateral BMB is recom-
mended, along with immunohistochemistry and flow cytometry.
PROGNOSTIC GROUPS AND TREATMENT ALLOCATION
The increased use of systemic and multimodality approaches has
made AnnArbor stage less relevant in directing the choice of therapy.
Nevertheless, we recommend amodification of the AnnArbor classi-
fication(Table2) foranatomicdescriptionofdisease extent.However,
regardless of stage, general practice is to treat patients basedon limited
(stages I and II, nonbulky) or advanced (stages III or IV) disease, with
stage IIbulkydisease considered limitedoradvancedasdeterminedby
histology and a number of prognostic factors. The designation E for
extranodal disease is relevant only for limited extranodal disease in the
absence of nodal involvement (IE) or in patients with stage II disease
and direct extension to a non-nodal site. E is not relevant to patients
with advanced-stage disease.
TheAnnArborclassificationsubdividespatients according to the
absence (A) or presence (B) of disease-related symptoms. However,
these features are frequentlyneither recordednor accurate.Moreover,
in the International Prognostic Index,12 Follicular Lymphoma Inter-
national Prognostic Index,13 Follicular Lymphoma International
Prognostic Index 2,15 Mantle Cell International Prognostic Index,14
andInternationalPrognosticScore,11 constitutional symptomsdonot
confer an unfavorable outcome. Thus, only patients with HL need be
assigned the designations A or B because symptoms only direct treat-
ment in that disease.
Summary
Excisionalbiopsy ispreferred fordiagnosis, althoughcore-needle
biopsy may suffice when not feasible.
Clinical evaluation includes careful history, relevant laboratory
tests, and recording of disease-related symptoms.
PET-CT is the standard forFDG-avid lymphomas,whereasCT is
indicated for nonavid histologies.
A modified Ann Arbor staging system is recommended; how-
ever, patients are treated according to prognostic and risk factors.
Suffixes A and B are only required for HL.
The designation X for bulky disease is no longer necessary; in-
stead, a recording of the largest tumor diameter is required.
If a PET-CT is performed, aBMB is no longer indicated forHL; a
BMB is only needed for DLBCL if the PET is negative and identifying
a discordant histology is important for patient management.
ASSESSMENT OF RESPONSE AFTER TREATMENT
End-of-treatment assessment is more accurate with PET-CT, espe-
cially forpatientswith radiologic (CT)CRuorpartial response (PR) in
HL, DLBCL, and follicular lymphoma.7,52-55 PET-CT–based criteria
eliminate CRu and improve the prognostic value of PR. In early- and
advanced-stagepatientswithHL, anegativepredictive valueof 95%to
100% and positive predictive value of more than 90% have been
reported.56,57 In aggressive NHL, studies have reported a negative
predictive value of 80% to 100%but a lower positive predictive value,
ranging from50%to100%.58-61 If further treatmentbasedon residual
metabolically active disease on PET-CT is being considered, either
biopsy or follow-up scan is advised. In these lymphoma subtypes,
response assessment with PET-CTmay be preferred.
The IWG criteria for reviewing PET scans were based on visual
interpretation and intended for end-of-treatment evaluation,62 using
mediastinal bloodpool as the comparator. The current recommenda-
tion is touse the 5-point scale, both for clinical trials including interim
analysis and for end-of-treatment assessment (Table 3).24 Interim
PET-CT is used to assess early treatment response and, at end of
treatment, to establish remission status. A score of 1 or 2 is considered
to represent completemetabolic response at interim and end of treat-
ment. FDGuptakedeclinesduring therapy in chemotherapy-sensitive
disease, and residual FDG uptake higher than normal liver uptake is
frequently seen at interim inpatientswho achieve completemetabolic
response at the end of treatment. More recent data also suggest that
most patients with uptake higher than mediastinum but less than or
equivalent to liver (score of 3) have good prognosis at the end of
treatment with standard therapy in HL,63 DLBCL,61 and follicular
lymphoma.54 However, in response-adapted trials exploring treat-
mentde-escalation, amorecautiousapproachmaybepreferred, judg-
ing a score of 3 to be an inadequate response to avoidundertreatment.
Therefore, interpretation of a score of 3 depends on the timing of
assessment, the clinical context, and the treatment. A score of 4 or 5 at
interim suggests chemotherapy-sensitive disease, provideduptakehas
reduced from baseline, and is considered to represent partial meta-
bolic response. At the end of treatment, residual metabolic disease
with a score of 4 or 5 represents treatment failure even if uptake has
reduced from baseline. A score of 4 or 5 with intensity that does not
change or even increases from baseline and/or new foci compatible
Table 2. Revised Staging System for Primary Nodal Lymphomas
Stage Involvement Extranodal (E) Status
Limited
I One node or a group of adjacent
nodes
Single extranodal lesions
without nodal
involvement
II Two or more nodal groups on the
same side of the diaphragm
Stage I or II by nodal
extent with limited
contiguous extranodal
involvement
II bulky II as above with “bulky” disease Not applicable
Advanced
III Nodes on both sides of the
diaphragm; nodes above the
diaphragm with spleen
involvement
Not applicable
IV Additional noncontiguous
extralymphatic involvement
Not applicable
NOTE. Extent of disease is determined by positron emission tomography–
computed tomography for avid lymphomas and computed tomography for
nonavid histologies. Tonsils, Waldeyer’s ring, and spleen are considered
nodal tissue.
Whether stage II bulky disease is treated as limited or advanced disease
may be determined by histology and a number of prognostic factors.
Cheson et al
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with lymphoma represents treatment failure at interim and at the
end-of-treatment assessment.
In most cases, lack of significant response can be interpreted
visually. Although ideally a quantitative cutoff might improve consis-
tency, there is insufficient evidence to quantify precisely the reduction
in uptake that predicts adequate response using FDG-PET for lym-
phoma, which is dependent on disease type, timing, and treatment
given.Recent data suggest that theCT scanmayplay a complimentary
role in patients with HL who have either a positive interim or post-
treatment PET-CT, with a greater reduction in tumor mass correlat-
ing with an improved outcome.64,65 How best to use this information
remains to be determined.
CT-based response is preferred for histologies with low or vari-
ableFDGavidityand inregionsof theworldwherePET-CTisunavail-
able. However, in the absence of a PET-CT scan, a mass that has
decreased in sizebutpersists is consideredatbest aPRin theabsenceof
biopsydocumenting absenceof lymphoma, and the former termCRu
is not to be considered.7 In trials exploring new agents in multiply
relapsed disease where data are lacking regarding PET-CT and where
assessment of disease control is more important than likelihood of
cure, CT-based response may also bemore relevant (Table 3).
At interim or end of therapy, tests that were abnormal before
treatment should be repeated, including assessment of extranodal
sites. Response assessment is detailed in Table 3 and in the follow-
ing sections.
Nodes or Extranodal Lesions That Split When Disease
Is Responding
If a confluent nodal mass splits into several discrete nodes, the
individual product of the perpendicular diameters (PPDs) of the
nodes should be summed together to represent the PPD of the split
lesion; this PPD is added to the sum of the PPDs of the remaining
lesions tomeasure response. If subsequent growthof anyor all of these
discrete nodes occurs, the nadir of each individual node is used to
determine progression (as if each individual node was selected as a
target lesion at baseline).
Nodes or Extranodal Lesions That Become Confluent
When Disease Is Progressing
If a group of target lymph nodes becomes confluent, the PPD of
the current confluent mass should be compared with the sum of the
PPDs of the individual nodes, with more than 50% increase in the
PPD of the confluent mass compared with the sum of individual
nodes necessary to indicate progressive disease. The LDi and shortest
diameter are no longer needed to determine progression.
Additional Response Assessment Guidelines
The presence of residual symptoms in the absence of detectable
disease by imaging does not preclude the designation CR. In the
context of an agent associated with a flare reaction, caution must be
exercised not to confuse the possible tumor flare with progressive
disease. It is recommended that either a biopsy be performed or the
lesion be reassessed in at least 2 weeks, and if there is continued
evidence of tumor progression, the date of progressive disease is the
previous evaluation.
FOLLOW-UP EVALUATIONS
Good clinical judgment, a careful history, and physical examination
are the cornerstones of patient follow-up. The IWG, National Com-
prehensive Cancer Network, and European Society for Medical On-
cology published recommendations for follow-up that vary by
histology(curablev incurable),whetherapatient isonaclinical trialor
managed with standard of care, or the clinical setting (eg, initial v
relapsed/refractory disease; complete response v PR to treat-
ment).7,66,67 For example, for curable histologies such as HL and
DLBCL, the likelihood of relapse decreases over time; thus, the fre-
quency of follow-up should decrease, with visits being reduced from
every 3months during the first 2 years, to every 6months for the next
3 years, and then annually thereafter to monitor for late relapse and
treatment-related adverse effects. In contrast, in follicular lymphoma,
mantle-cell lymphoma, andother incurable histologies, the likelihood
of recurrence continues or increases over time, and patients should be
observed every 3 to 6 months, determined by pretreatment risk fac-
tors, whether the patient is being managed conservatively, and
whether treatment has achieved a complete or less than complete
response. In addition, a CBC, metabolic panel, and serum lactate
dehydrogenase are recommended.
Published studies fail to support routine surveillance scans, and
they are discouraged.68-70 The false-positive rate with PET scans is
greater than 20%, leading to unnecessary investigations, radiation
exposure, biopsies, expense, and patient anxiety. Follow-up scans
should be prompted by clinical indications. In clinical trials with
time-dependent end points (eg, progression-free survival, event-free
survival), a CT scan is determined by the study-designated interval. In
the indolent lymphomas, asymptomatic intra-abdominal or retroper-
itoneal disease progressionmay be a concern in patients with residual
disease in those areas after therapy. In such patients, judicious use of
scans can be considered. In clinical practice and in clinical trials,
attempts should be made to limit the number of scans to which a
patient is exposed.
Summary
PET-CT should be used for response assessment in FDG-avid
histologies, using the 5-point scale; CT is preferred for low or variable
FDG avidity.
A complete metabolic response even with a persistent mass is
considered a complete remission.
A PR requires a decrease by more than 50% in the sum of the
product of the perpendicular diameters of up to six representative
nodes or extranodal lesions.
Progressive disease byCT criteria only requires an increase in the
PPDs of a single node by 50%.
Surveillance scans after remission are discouraged, especially for
DLBCL and HL, although a repeat study may be considered after an
equivocal finding after treatment.
Judicious use of follow-up scans may be considered in
indolent lymphomas with residual intra-abdominal or retro-
peritoneal disease.
MEASUREMENT OF OUTCOME
Definitions are consistent with the IWG definitions.7
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Table 3. Revised Criteria for Response Assessment
Response and Site PET-CT–Based Response CT-Based Response
Complete Complete metabolic response Complete radiologic response (all of the following)
Lymph nodes and
extralymphatic sites
Score 1, 2, or 3 with or without a residual mass on 5PS† Target nodes/nodal masses must regress to  1.5 cm in LDi
It is recognized that in Waldeyer’s ring or extranodal sites
with high physiologic uptake or with activation within
spleen or marrow (eg, with chemotherapy or myeloid
colony-stimulating factors), uptake may be greater than
normal mediastinum and/or liver. In this circumstance,
complete metabolic response may be inferred if uptake at
sites of initial involvement is no greater than surrounding
normal tissue even if the tissue has high physiologic
uptake
No extralymphatic sites of disease
Nonmeasured lesion Not applicable Absent
Organ enlargement Not applicable Regress to normal
New lesions None None
Bone marrow No evidence of FDG-avid disease in marrow Normal by morphology; if indeterminate, IHC negative
Partial Partial metabolic response Partial remission (all of the following)
Lymph nodes and
extralymphatic sites
Score 4 or 5† with reduced uptake compared with baseline
and residual mass(es) of any size
 50% decrease in SPD of up to 6 target measurable nodes
and extranodal sites
At interim, these findings suggest responding disease When a lesion is too small to measure on CT, assign 5 mm  5
mm as the default value
At end of treatment, these findings indicate residual disease When no longer visible, 0  0 mm
For a node  5 mm  5 mm, but smaller than normal, use
actual measurement for calculation
Nonmeasured lesions Not applicable Absent/normal, regressed, but no increase
Organ enlargement Not applicable Spleen must have regressed by  50% in length beyond
normal
New lesions None None
Bone marrow Residual uptake higher than uptake in normal marrow but
reduced compared with baseline (diffuse uptake
compatible with reactive changes from chemotherapy
allowed). If there are persistent focal changes in the
marrow in the context of a nodal response, consideration
should be given to further evaluation with MRI or biopsy
or an interval scan
Not applicable
No response or stable disease No metabolic response Stable disease
Target nodes/nodal masses,
extranodal lesions
Score 4 or 5 with no significant change in FDG uptake from
baseline at interim or end of treatment
 50% decrease from baseline in SPD of up to 6 dominant,
measurable nodes and extranodal sites; no criteria for
progressive disease are met
Nonmeasured lesions Not applicable No increase consistent with progression
Organ enlargement Not applicable No increase consistent with progression
New lesions None None
Bone marrow No change from baseline Not applicable
Progressive disease Progressive metabolic disease Progressive disease requires at least 1 of the following
Individual target nodes/nodal
masses
Score 4 or 5 with an increase in intensity of uptake from
baseline and/or
PPD progression:
Extranodal lesions New FDG-avid foci consistent with lymphoma at interim or
end-of-treatment assessment
An individual node/lesion must be abnormal with:
LDi  1.5 cm and
Increase by  50% from PPD nadir and
An increase in LDi or SDi from nadir
0.5 cm for lesions  2 cm
1.0 cm for lesions  2 cm
In the setting of splenomegaly, the splenic length must
increase by  50% of the extent of its prior increase
beyond baseline (eg, a 15-cm spleen must increase to
 16 cm). If no prior splenomegaly, must increase by at
least 2 cm from baseline
New or recurrent splenomegaly
Nonmeasured lesions None New or clear progression of preexisting nonmeasured
lesions
(continued on following page)
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CONCLUDING REMARKS
Accurate pretreatment evaluation and response assessment are
critical to the optimal management of patients with lymphoma.
With increasing knowledge of the disease, new prognostic factors,
and a better understanding of tumor biology comes a need to
update prior systems. Despite the importance of a physical exam-
ination, imaging studies have become the standard. The present
recommendations are directed primarily at initial staging and as-
sessment, and their role in the multiply relapsed setting and early
clinical trials remains to be confirmed. Amajor departure from the
Ann Arbor system and the IWG criteria is that PET-CT is included
in staging for FDG-avid lymphomas, because it is more sensitive
than CT and provides a baseline against which response is more
accurately assessed. Patients should be treated based on prognostic
factors. Subclassification of A and B is now only indicated if prog-
nostically important (ie, HL). Patients, including those with HL
and most with DLBCL, can be spared a staging BMB,71 and a
routine chest x-ray is unnecessary for staging, although it may be
useful for monitoring select patients with HL. Although the cur-
rent definition of bulk is retained for HL, further correlations
between maximum tumor diameter and outcome are needed to
provide a clinically meaningful definition of bulk with current
treatment approaches for NHL. Response assessment is preferred
for FDG-avid lymphomas where possible, using the 5-point scale,
whereas CT-based response remains important in lymphomas
with low or variable FDG avidity, and in multiply relapsed disease,
CT criteria for progressive disease can be based on an increase of a
single lesion. The better we are able to exploit the biology of
lymphomas for therapeutic benefit, the more our treatment strat-
egies will be determined by relevant receptors and pathways, with
even less reliance on Ann Arbor staging. Hopefully, the current
recommendations will provide the necessary standardization of
clinical trial conduct and interpretation that leads to improved
therapies for patients with lymphoma.
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Table 3. Revised Criteria for Response Assessment (continued)
Response and Site PET-CT–Based Response CT-Based Response
New lesions New FDG-avid foci consistent with lymphoma rather than
another etiology (eg, infection, inflammation). If
uncertain regarding etiology of new lesions, biopsy or
interval scan may be considered
Regrowth of previously resolved lesions
A new node  1.5 cm in any axis
A new extranodal site  1.0 cm in any axis; if  1.0 cm in
any axis, its presence must be unequivocal and must be
attributable to lymphoma
Assessable disease of any size unequivocally attributable to
lymphoma
Bone marrow New or recurrent FDG-avid foci New or recurrent involvement
Abbreviations: 5PS, 5-point scale; CT, computed tomography; FDG, fluorodeoxyglucose; IHC, immunohistochemistry; LDi, longest transverse diameter of a lesion;
MRI, magnetic resonance imaging; PET, positron emission tomography; PPD, cross product of the LDi and perpendicular diameter; SDi, shortest axis perpendicular
to the LDi; SPD, sum of the product of the perpendicular diameters for multiple lesions.
A score of 3 in many patients indicates a good prognosis with standard treatment, especially if at the time of an interim scan. However, in trials involving
PET where de-escalation is investigated, it may be preferable to consider a score of 3 as inadequate response (to avoid undertreatment). Measured dominant
lesions: Up to six of the largest dominant nodes, nodal masses, and extranodal lesions selected to be clearly measurable in two diameters. Nodes should
preferably be from disparate regions of the body and should include, where applicable, mediastinal and retroperitoneal areas. Non-nodal lesions include those
in solid organs (eg, liver, spleen, kidneys, lungs), GI involvement, cutaneous lesions, or those noted on palpation. Nonmeasured lesions: Any disease not
selected as measured, dominant disease and truly assessable disease should be considered not measured. These sites include any nodes, nodal masses,
and extranodal sites not selected as dominant or measurable or that do not meet the requirements for measurability but are still considered abnormal, as well
as truly assessable disease, which is any site of suspected disease that would be difficult to follow quantitatively with measurement, including pleural
effusions, ascites, bone lesions, leptomeningeal disease, abdominal masses, and other lesions that cannot be confirmed and followed by imaging. In
Waldeyer’s ring or in extranodal sites (eg, GI tract, liver, bone marrow), FDG uptake may be greater than in the mediastinum with complete metabolic
response, but should be no higher than surrounding normal physiologic uptake (eg, with marrow activation as a result of chemotherapy or myeloid
growth factors).
†PET 5PS: 1, no uptake above background; 2, uptakemediastinum; 3, uptakemediastinum but liver; 4, uptake moderately liver; 5, uptake markedly higher
than liver and/or new lesions; X, new areas of uptake unlikely to be related to lymphoma.
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